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Abstract Diabetic kidney disease, diagnosed by urinary
albumin excretion rate (AER), is a critical symptom of
chronic vascular injury in diabetes, and is associated with
dyslipidemia and increased mortality. We investigated
serum lipids in 326 subjects with type 1 diabetes: 56%
of patients had normal AER, 17% had microalbuminuria
(20 B AER\200 lg/min or 30 B AER\300 mg/24 h)
and 26% had overt kidney disease (macroalbuminuria
AER C 200 lg/min or AER C 300 mg/24 h). Lipoprotein
subclass lipids and low-molecular-weight metabolites were
quantiﬁed from native serum, and individual lipid species
from the lipid extract of the native sample, using a proton
NMR metabonomics platform. Sphingomyelin (odds ratio
2.53, P\10
-7), large VLDL cholesterol (odds ratio 2.36,
P\10
-10), total triglycerides (odds ratio 1.88, P\10
-6),
omega-9andsaturatedfattyacids(oddsratio1.82,P\10
-5),
glucose disposal rate (odds ratio 0.44, P\10
-9), large HDL
cholesterol (odds ratio 0.39, P\10
-9) and glomerular ﬁl-
trationrate(odds ratio0.19,P\10
-10) were associated with
kidney disease. No associations were found for polyunsatu-
rated fatty acids or phospholipids. Sphingomyelin was a sig-
niﬁcant regressor of urinary albumin (P\0.0001) in
multivariate analysis with kidney function, glycemic control,
body mass, blood pressure, triglycerides and HDL choles-
terol.Kidneyinjury,sphingolipidsandexcessfattyacidshave
been linked in animal models—our exploratory approach
provides independent support for this relationship in human
patients with diabetes.
Keywords Diabetic nephropathy  NMR metabonomics 
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1 Introduction
Type 1 diabetes follows the autoimmune destruction of
pancreatic beta-cells at a young age. Acute symptoms can
be controlled by insulin injections, but the diabetes-related
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plications (Lithovius et al. 2011). An estimated third of
patients with long-standing type 1 diabetes are affected by
kidney disease, which is characterized by increased urinary
albumin excretion, high blood pressure and a gradual
decline in glomerular ﬁltration (Gross et al. 2005;M a ¨kinen
et al. 2008a). For individual prognosis, kidney disease is
the crucial feature: it is associated with a ten-fold increase
in mortality, often from cardiovascular disease or stroke
before end-stage renal disease is reached (Forsblom et al.
2011; Groop et al. 2009; Morrish et al. 2001; Stadler et al.
2006).
Obesity, selective insulin resistance and lipotoxicity are
recognized as important aspects of end-organ damage in
diabetes (Groop et al. 2005). Adipose tissue in a state of
over-nutrition can trigger the release of pro-inﬂammatory
agents (Kennedy et al. 2009; Surmi and Hasty 2010),
which could explain some of the observed chronic
inﬂammation in atherosclerosis and diabetic kidney disease
(Best et al. 2005; Cao et al. 2007; Saraheimo et al. 2003).
Furthermore, a large proportion of type 1 diabetic patients
satisfy the metabolic syndrome deﬁnition and particularly
the dyslipidemia component of the deﬁnition increases the
likelihood of complications and premature death (Ma ¨kinen
et al. 2008a; Thorn et al. 2005; Tolonen et al. 2009).
Accordingly, the triglyceride-rich VLDL and cholesterol-
carrying HDL subclasses are important covariates of dia-
betic complications (Jenkins et al. 2003; Soedamah-Muthu
et al. 2003).
Various and partly conﬂicting differences in serum lipid
species have been detected in high-risk children and type 1
diabetic patients (Fievet et al. 1990; Jain et al. 2000; Oresic
et al. 2008; Seigneur et al. 1994). Serum phospholipids have
been studied as structural components of lipoproteins, but
their relevance for type 1 diabetes complications is not fully
known (Bagdade and Subbaiah 1989; Watala and Jo ´zwiak
1990); sphingolipids have been associated with numerous
diseases (Boini et al. 2010; Fox et al. 2011; Hicks et al.
2009; Piperi et al. 2004; Summers 2010), but their signiﬁ-
cance for human diabetic kidney disease needs clariﬁcation.
Dietary polyunsaturated fatty acids are considered beneﬁ-
cial (Lee et al. 2010; Mori et al. 1989) whereas saturated
fatty acids are likely to be harmful also in type 1 diabetes.
However, information on serum lipid concentrations in type
1 diabetic subjects remains fragmented.
Metabonomics has the potential to recognize previously
unconsidered associations between metabolic products and
clinical end-points (Ala-Korpela 2007;M a ¨kinen et al.
2006). In this study, we investigate a number of lipids and
other biochemical measures in a set of human subjects with
long-standing type 1 diabetes with and without complica-
tions. Our aim is to ﬁnd those biochemical quantities that
are associated with the (i) diagnostic classiﬁcation and (ii)
continuous markers of kidney injury. The ﬁndings provide
clues on the lipid mediators of vascular damage and bio-
marker candidates for further mechanistic and epidemio-
logical studies.
2 Methods
We studied 326 type 1 diabetic patients (218 men and 108
women) as part of the Finnish Diabetic Nephropathy Study
(Ma ¨kinen et al. 2008a). The data collection was cross-
sectional (serum and urine samples), but with longitudinal
records of albuminuria and clinical history. Type 1 diabetes
mellitus was deﬁned as an age of onset below 35 years and
initiation of insulin treatment within a year of onset.
The clinical characteristics are listed in Table 1. The
normal range of urinary albumin excretion rate (AER)
Table 1 Summary of clinical
characteristics
Median and 95% interval are
reported for continuous
variables. Abbreviations: type 1
diabetes (T1DM), urinary
albumin excretion rate (AER),
estimated glomerular ﬁltration
rate (eGFR), efﬁcient glucose
disposal rate (eGDR).
* Hospital records. ** Central
laboratory
No kidney disease Diabetic kidney disease P-value
Number 240 86 –
Normal AER* 76% 0% –
Microalbuminuria* 24% 0% –
Macroalbuminuria* 0% 100% –
Age (years) 34 (18–60) 42 (24–58) 1.3 9 10
-6
Diabetes duration (years) 16 (2–47) 29 (16–43) 3.8 9 10
-14
Men 67% 67% 0.90
24 h-AER (mg)** 18 (5–269) 908 (26–5437) 4.5 9 10
-38
eGFR (mL/min per 1.73 m
2) 99 (62–152) 50 (13–112) 3.6 9 10
-27
Retinopathy 20% 78% 7.8 9 10
-16
Metabolic syndrome 23% 49% 6.4 9 10
-6
eGDR (mg/kg per min) 6.6 (2.3–10.3) 4.4 (2.5–7.0) 1.7 9 10
-13
Anti-hypertensive medication 29% 95% \10
-17
Lipid medication 10% 20% 0.011
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123was deﬁned as AER\20 lg/min for night urine or
AER\30 mg/24 h for a timed circadian collection. Overt
kidney disease was diagnosed if AER C 200 lg/min or
AER C 300 mg/24 h (macroalbuminuria). The intermedi-
ary range (microalbuminuria, 20 B AER\200 lg/min or
30 B AER\300 mg/24 h) represents a clinically chal-
lenging borderline with no clear consensus on pathology.
In this study, microalbuminuria was regarded as not having
kidney disease, since we could not see reduced kidney
function. AER exhibits a large daily variance and the
kidney diagnosis was based on at least two out of three
consecutive albumin tests. We also measured urinary
albumin centrally from a single 24 h collection to obtain a
continuous renal status (denoted by 24 h-AER). Laser
treatment of the retina was used as an indicator of prolif-
erative retinopathy.
The metabolic syndrome was deﬁned according to the
NCEP ATP III criteria and glomerular ﬁltration rate was
estimated by the Cockcroft-Gault formula. Efﬁcient glu-
cose disposal rate was estimated according to the Williams-
Orchard formula 24.4–12.97 9 waist-hip ratio -3.39 9
hypertension -0.60 9 hemoglobin A1c, where hyperten-
sion was deﬁned as systolic/diastolic [140/90 mmHg or
anti-hypertensive medication.
The proton NMR experiments were performed on a
platform with three molecular windows (Ma ¨kinen et al.
2008b; Tukiainen et al. 2008). Two windows were applied
to native serum: the LIPO window yields information on
lipoprotein subclasses and the LMWM window on a
number of low-molecular-weight metabolites. The third
window, denoted by LIPID, was applied to serum lipid
extract to measure the serum lipid constituents and the
diversity of fatty acid saturation. The current methodo-
logical and metabolite details for the serum NMR meta-
bolomics, including spectral characteristics and metabolite
assignments for all the three molecular windows, have been
published previously (Inouye et al. 2010). Information on
other biochemical and clinical variables can be found in
(Ma ¨kinen et al. 2008a).
Odds ratios for kidney disease were calculated by uni-
variate logistic regression for each continuous variable
(clinical, biochemical and NMR), respectively. Before
analysis, the variables were rank transformed to produce
comparable results. Adjustments for age, diabetes duration
and gender were made by linear regression. Statistical
signiﬁcance and 95% conﬁdence intervals were estimated
by bootstrap simulation. The reported P-values are not
corrected for multiple testing, but the Bonferroni signiﬁ-
cance limit is listed in the ﬁgure and table captions. The
associations between continuous variables and 24 h-AER
were estimated by the Spearman correlation coefﬁcient.
Multivariate linear regression was applied to two sets of
variables that were chosen based on prior biological
knowledge. The ﬁrst set includes multivariate formulas for
the metabolic syndrome, glomerular ﬁltration and glucose
disposal rate. The second set contains directly measured
quantities such as blood pressure, hemoglobin A1c and
serum creatinine that reﬂect established vascular risk fac-
tors. Set 1 represents a clinically motivated dimension
reduction, whereas Set 2 works as an a priori variable
selection. We also tested ridge regression and projection to
latent structures (PLS), however, neither method could
produce robust estimates for the regression coefﬁcients due
to the collinearity between the variables (data not shown).
3 Results and discussion
Figure 1 shows the logistic odds ratios (OR) for kidney
disease—adjusted by diabetes duration, age and gender—
for a subset of variables. The full list is available in Sup-
plement1.Serum creatinine, cystatin-C and urea are cleared
by the kidneys, so a reduction in the ﬁltration capacity has a
direct effect on their concentrations (OR C 3.25, P B
3.4 9 10
-8), and on the creatinine-based estimate of glo-
merular ﬁltration rate (OR = 0.19, P = 8.2 9 10
-11).
Sphingomyelin (OR = 2.53, P = 1.5 9 10
-8) and large
HDL particles (OR B 0.40, P B 3.1 9 10
-10) are the
strongest regressors after the established kidney biomark-
ers. Furthermore, medium HDL particles (OR B 0.60,
P B 6.6 9 10
-5) and lipids in small HDL (OR = 0.62,
P = 0.00031) are inversely associated with kidney disease.
Extra large and large VLDL particles have the highest ORs
after sphingomyelin (OR C 1.95, P B 1.4 9 10
-7).
Monounsaturated 16:1 and 18:1 and omega-9 and saturated
fatty acids have a stronger association with kidney disease
(OR C 1.82, P B 3.5 9 10
-6) than omega-6 and 7 (OR =
1.59, P = 0.00029), 18:2 (no association), omega-3 (no
association), 22:6 (no association) or other polyunsaturated
fatty acids (OR = 0.76, P = 0.020).
Odds ratios for retinopathy were also estimated by
logistic regression: only24 h-AER(OR = 1.75, P = 9.3 9
10
-6), serum creatinine (OR = 1.52, P = 0.00028), efﬁ-
cient glucose disposal rate (OR = 0.55, P = 2.6 9 10
-6)
and glomerular ﬁltration (OR = 0.62, P = 5.4 9 10
-5)
were signiﬁcant regressors after adjusting for diabetes
duration, age and gender.
To complement the categorical analysis, we also cal-
culated correlations between the centrally measured con-
tinuous 24 h-AER, and the other clinical and biochemical
variables. Table 2 highlights the important correlations and
the full list is available in Supplement 2. Serum creatinine
is strongly correlated with 24 h-AER (r = 0.73, P\
10
-17), as expected. Sphingomyelin is again the top lipid
variable (r = 0.42, P = 1.5 9 10
-14), followed by systolic
blood pressure, total triglycerides and large VLDL
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123cholesterol. Glomerular ﬁltration rate, cholesterol in large
HDL and efﬁcient glucose disposal rate are inversely
associated with 24 h-AER.
We chose two sets of variables that represent established
risk factors for diabetic kidney disease to explain the
covariance between sphingomyelin and 24 h-AER
(Table 3). Set 1 includes derived clinical traits (such as the
metabolic syndrome), whereas Set 2 includes measures that
represent diagnostic components: waist circumference for
obesity, systolic blood pressure for hypertension, hemo-
globin A1c for glycemic control, triglycerides and HDL
cholesterol for dyslipidemia and serum creatinine for kid-
ney function. Sphingomyelin is a statistically signiﬁcant
trait in both models (P B 1.8 9 10
-5), which suggests that
it may reﬂect previously undetected biological phenomena
that are speciﬁc to albuminuria.
Models of the binary kidney disease diagnosis and reti-
nopathy are available in Supplement 3. Kidney disease is
Fig. 1 Odds ratios for diabetic
kidney disease, adjusted by
diabetes duration, age and
gender. The circles indicate
logarithmic ORs (regression
coefﬁcients in the logistic
model) and the horizontal lines
show the 95% interval. The fold
change was calculated by
dividing the median
concentration difference (after
adjustments) between the cases
and controls by the median
concentration in the control
group. Only those variables that
reached Bonferroni multiple
testing signiﬁcance are included
(P\0.00038)
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123associatedwithglomerularﬁltrationandsphingomyelininSet
1, and with serum creatinine, HDL cholesterol, sphingomy-
elin and diabetes duration in Set 2. Retinopathy is strongly
related to diabetes duration, but not to sphingomyelin.
Sphingomyelin is correlated with glomerular ﬁltration
rate (r = –0.32, P\10
-6), but this study cannot ascertain
the causal relationships between albuminuria, declining
kidney function and lipotoxicity. The selection of study
subjects is another limitation: although matched for gender,
the patients without kidney disease had a shorter diabetes
duration. It is therefore possible that some of the controls
were in an early phase of kidney disease, which could have
diluted the results.
A recent animal study demonstrated how the manipula-
tion of the sphingolipid pathway could alleviate kidney
disease: untreated mice on a high-fat diet developed insulin
resistance and albuminuria, but a pharmacological inter-
vention reduced the effects (Boini et al. 2010). By inhibiting
the conversion of sphingomyelin into ceramide, the authors
were able to signiﬁcantly decrease glomerular injury and
restore urinary albumin excretion rate to normal range.
The proportional increase of sphingomyelin in the kid-
ney disease group was modest (?17% when adjusted by
aging and gender) and much of the variance was shared
with other clinical characteristics, which suggests that
excess circulating sphingomyelin might be a by-product of
the disease process rather than an active initiator. In fact,
excess saturated fatty acids may be the underlying cause:
they are substrates for sphingolipid synthesis, they promote
lipotoxicity (production of ceramides) and are also linked
to insulin resistance (Bunn et al. 2010; Kennedy et al.
2009; Yang et al. 2009). The NMR method cannot distin-
guish between omega-9 and saturated fatty acid chains, but
the combination was nevertheless signiﬁcantly correlated
with clinical kidney disease (Fig. 1) and 24 h-AER
(Table 2), whereas polyunsaturated fatty acids such as 18:2
or 22:6 showed no association.
4 Concluding remarks
Sphingomyelin emerged as a signiﬁcant biochemical
covariate of urinary albumin excretion in human type 1
diabetes, and the strongest lipid regressor for kidney dis-
ease. We also reproduced the associations between mac-
roalbuminuria and high triglycerides, excess serum fatty
acids and altered VLDL-HDL balance. Phospholipids or
polyunsaturated fatty acids were not covariates of albu-
minuria. Our results are supported by animal data, which
suggests that sphingolipids may reﬂect some of the
Table 2 A representative set of variables that are signiﬁcantly correlated with 24 h-AER. Correlation was measured by the Spearman coefﬁcient
and the Bonferroni multiple testing limit is at P\0.00038
Adjusted by diabetes duration, age and gender Unadjusted
Correlation P-value Correlation P-value
Serum creatinine 0.73 \10
-17 0.52 \10
-17
Sphingomyelin 0.42 1.5 9 10
-14 0.43 6.7 9 10
-16
Systolic blood pressure 0.31 4.7 9 10
-8 0.32 1.5 9 10
-8
Triglycerides 0.30 3.7 9 10
-7 0.38 1.6 9 10
-10
Large VLDL cholesterol 0.30 1.2 9 10
-7 0.29 1.4 9 10
-7
Free cholesterol 0.29 3.0 9 10
-7 0.32 9.2 9 10
-9
Omega-9 and saturated fatty acids 0.26 3.3 9 10
-6 0.33 1.8 9 10
-9
Omega-6 and 7 fatty acids 0.26 5.3 9 10
-6 0.26 4.3 9 10
-6
IDL triglycerides 0.22 0.00011 0.27 1.8 9 10
-6
Serum adiponectin 0.15 0.017 0.26 2.4 9 10
-5
Phosphoglycerides 0.12 0.036 0.16 0.0041
Diabetes duration 0.03 0.64 0.38 4.2 9 10
-12
Phosphatidylcholine -0.02 0.71 0.00 0.96
Omega-3 fatty acids -0.05 0.39 -0.03 0.60
Fatty acid length -0.20 0.00040 -0.25 6.6 9 10
-6
Medium HDL cholesterol -0.25 1.2 9 10
-5 -0.28 5.7 9 10
-7
HDL cholesterol -0.31 2.1 9 10
-7 -0.27 4.9 9 10
-6
Large HDL cholesterol -0.33 3.6 9 10
-9 -0.32 7.7 9 10
-9
Efﬁcient glucose disposal rate -0.33 8.2 9 10
-9 -0.51 \10
-17
Glomerular ﬁltration rate -0.45 3.3 9 10
-16 -0.43 1.2 9 10
-14
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123molecular links between microvascular injury, insulin
resistance, and saturated fatty acids. Further research of the
sphingolipid pathway may thus yield more sensitive phe-
notyping measures and new pharmacological options to
ease the burden of diabetic complications.
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